













 <p>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</p>		ATTY. DOCKET NO.		APPLICATION NO.	
		18528.636		10/629,649	
		APPLICANTS			
		Nigel R.A. BEELEY <i>et al.</i>			
FILING DATE		GROUP			
July 30, 2003		To Be Assigned			
U.S. PATENT DOCUMENTS					
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)					Reference Provided
	AA1	Ahles, "Toward a New Approach: Primary and Preventive Care of the Woman with Polycystic Ovarian Syndrome", <u>Prim. Care Update Ob/Gyns.</u> , 7(6):275-278 (2000)			10/317,126
	AB1	Balen, "Ovulation Induction for Polycystic Ovary Syndrome", <u>Human Fertility</u> , 3:106-111 (2000)			10/317,126
	AC1	Barbieri, "Induction of Ovulation in Infertile Women with Hyperandrogenism and Insulin Resistance", <u>Am. J. Obstet. Gynecol.</u> , 183(6):1412-1418 (2000)			10/317,126
	AD1	Ciampelli and Lanzone, "Insulin and Polycystic Ovary Syndrome: a New Look at an Old Subject", <u>Gynecol. Endocrinol.</u> , 12:277-292 (1998)			10/317,126
	AE1	Conway, "Hyperinsulinaemia and Polycystic Ovary Syndrome", <u>Human Fertility</u> , 3:93-95 (2000)			10/317,126
	AF1	Davison, "New Approaches to Insulin Resistance in Polycystic Ovarian Syndrome", <u>Current Opinion in Obstetrics and Gynecology</u> , 10:193-198 (1998)			10/317,126
	AH1	Ehrmann, "Relation and Functional Ovarian Hyperandrogenism to Non-Insulin Dependent Diabetes Mellitus", <u>Baillière's Clinical Obstetrics and Gynaecology</u> , 11(2):335-347 (1997)			10/317,126
	AI1	Franks, "Polycystic Ovary Syndrome", <u>Medical Progress</u> , 333(13):853-861 (1995)			10/317,126
	AJ1	Franks <i>et al.</i> , "Insulin Action in the Normal and Polycystic Ovary", <u>Endocrinology and Metabolism Clinics of North America</u> , 28(2):361-378 (1999)			10/317,126
	AK1	Hadine <i>et al.</i> , "Editorial: Polycystic Ovarian Syndrome - Relationship to Epilepsy and Antiepileptic Drug Therapy", <u>J. Clin. Endocrinology & Metabolism</u> , 86(7):2946-2949 (2001)			10/317,126
	AL1	Hopkinson <i>et al.</i> , "Polycystic Ovarian Syndrome: the Metabolic Syndrome Comes to Gynaecology", <u>BMJ</u> , 317:329-332 (1998)			10/317,126
	AM1	Iuorno <i>et al.</i> , "Insulin-Lowering Drugs in Polycystic Ovary Syndrome", <u>Obstetrics and Gynecology Clinics of North America</u> , 28(1):153-164 (2001)			10/317,126
EXAMINER				DATE CONSIDERED	
					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.636

APPLICATION NO.

10/629,649

APPLICANTS

Nigel R.A. BEELEY *et al.*

FILING DATE

July 30, 2003

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Reference Provided

JA	AA2	Kim <i>et al.</i> , "Insulin Sensitizers and Polycystic Ovary Syndrome: Can a Diabetes Medication Treat Infertility?", <u>Fertility and Sterility</u> , 73(6):1097-1098 (2000)	10/317,126
JA	AB2	Legro, "Polycystic Ovary Syndrome: Current and Future Treatment Paradigms", <u>Am. J. Obstet. Gynecol.</u> , 179(6), part 2, pp. S101-S108 (1998)	10/317,126
JA	AC2	Nestler, "Role of Hyperinsulinemia in the Pathogenesis of the Polycystic Ovary Syndrome, and Its Clinical Implications", <u>Seminars in Reproductive Endocrinology</u> , 15(2):111-122 (1997)	10/317,126
JA	AD2	Olefsky and Saltiel, "PPAR γ and the Treatment of Insulin Resistance", <u>TEM</u> , 11(9):362-367 (2000)	10/317,126
JA	AE2	Phipps, "Polycystic Ovary Syndrome and Ovulation Induction", <u>Obstetrics and Gynecology Clinics of North America</u> , 28(1):165-182 (2001)	10/317,126
JA	AF2	Pugeat and Ducluzeau, "Insulin Resistance, Polycystic Ovary Syndrome and Metformin", <u>Drugs</u> , 58 Suppl. 1:41-46 (1999)	10/317,126
JA	AH2	Rosenfield, "Current Concepts of Polycystic Ovary Syndrome", <u>Baillière's Clinical Obstetrics and Gynaecology</u> , 11(2):307-333 (1997)	10/317,126
JA	AI2	Spiegelman, "PPAR γ in Monocytes: Less Pain, Any Gain?", <u>Cell</u> , 93:153-155 (1998)	10/317,126
JA	AJ2	Udoff and Adashi, "Polycystic Ovarian Disease: A New Look at an Old Subject", <u>Current Opinion in Obstetrics and Gynecology</u> , 7:340-343 (1995)	10/317,126
JA	AK2	Utiger, "Insulin and the Polycystic Ovary Syndrome", <u>The New England Journal of Medicine</u> , 335(9):657-658 (August 27, 1996)	10/317,126
JA	AL2	Wolf, "Ovulation Induction", <u>Clinical Obstetrics and Gynecology</u> , 43(4):902-915 (2000)	10/317,126
JA	AM2	Zacur, "Polycystic Ovary Syndrome, Hyperandrogenism, and Insulin Resistance", <u>Obstetrics and Gynecology Clinics of North America</u> , 28(1):21-33 (2001)	10/317,126


EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

November 3 2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/629,649
Filing Date	July 30, 2003
First Named Inventor	Beeley
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	0212-CIP-9

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Jeffrey E. Russell

Date	
Considered	

November 3, 2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.